Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography

Table 2 Clinical and biochemical characteristics of patients in this study

	All	Control	Icodextrin	p
N (%)	49	23 (46.9)	26 (53.1)
Male (%)	38 (77.6)	19 (82.6)	19 (73.1)	0.51
Age	64.1±11.8	64.9±12.5	63.5±11.4	0.69
Height (cm)	160.9±9.9	159.9±10.1	161.8±9.8	0.50
Weight (kg)	60.6±11.9	57.2±11.2	63.6±11.9	0.06
BMI	23.3±3.7	22.3±3.6	24.2±3.5	0.07
DM (%)	21 (42.8)	7 (30.4)	14 (53.8)	0.15
Dyslipidemia (%)	34 (69.4)	19 (82.6)	15 (57.7)	0.06
Statin use (%)	16 (32.6)	8 (34.8)	8 (30.8)	0.77
Creatinine (mg/dl)	10.3±3.4	10.0±3.5	10.6±3.3	0.48
Albumin (g/dl)	3.3±0.5	3.4±0.5	3.2±0.4	0.20
CRP (mg/dl)	0.41±1.0	0.45±1.3	0.38±0.6	0.80
Glucose (mg/dl)	116.1±30.6	109.4±24.2	122.2±34.8	0.15
PD vintage (months)	39.9±28.5	42.1±30.5	37.9±27.1	0.61
D/P Cr	0.63±0.13	0.56±0.13	0.68±0.11	0.002

Values are expressed as mean ± standard deviation. The values are compared between the groups by the chi-square test or t-test.
Abbreviations: control control group, icodextrin icodextrin group, BMI body mass index, DM diabetes mellitus, CRP C-reactive protein, PD peritoneal dialysis, D/P Cr dialysate/plasma creatinine ratio.

ISSN: 1471-2369